Document text
Principal Investigator: Meredith Hay
Organization: UNIVERSITY OF ARIZONA
Fiscal Year: 2024
Award: $1,707,517
Funding agency: National Institute on Aging
PROJECT SUMMARY
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer's disease related dementias
(ADRD) significantly contribute to the 55 million people world-wide who suffer with dementia. This number is
estimated to increase to over 139 million people by 2050 (WHO). A number of studies have shown that VCID and
conversion to ADRD are strongly correlated with vascular disease, inflammation and decreased cerebral brain
blood flow 1,2,3, 4,5,6, 7,8. The relationship between vascular disease, cognitive function and progression to
dementia and possible AD have been recently reviewed 9. These authors successfully make the case for a close
relationship between cardiovascular risk factors and risk for VCID and ADRD. Furthermore, conversion rates of
VCI to dementia has been reported to be within 40-46% within 5 years of diagnosis of VCI 10,11. There is an
urgent unmet medical need for therapeutics to prevent cognitive decline in individuals at risk for VCID.
The goal of this proposed late-stage NIA U01 ADDP program is to complete FDA-required long-term toxicology
and safety studies required to advance to a Phase 2 clinical trial of the anti-inflammatory peptide, PNA5, for
treatment of persons with MCI and are at risk for VCID/ADRD. The peptide PNA5 is a novel pleotropic anti-
inflammatory Angiotensin-(1-7)/MasR agonist that has outstanding brain penetration, enhanced bioavailability,
decreases brain and cerebrovascular inflammation, improves cerebral blood flow and restores cognitive function
in our preclinical VCID model 12,13,14,15. None of the other published studies with oral formulations of Ang-(1-7)
related peptides or small molecules 18,19,20 have exhibited the excellent brain penetration that we have observed
with our glycosylated peptides, which will be key for developing an effective CNS anti-inflammatory, cognitive
protective therapeutic. With support from the NIA, we are completing our early stage ADDP program, have
successfully completed our FDA pre-IND meeting, and will have our new FDA IND for PNA5 by Q3 2023. By the
time of this review, we will have completed our formal initial 28-day toxicology and safety work for PNA5 required
for Phase 1a first-in-human safety studies. In this application we are requesting support for 1) additional long-
term exposure safety analysis,2) expanded GMP manufacturing and final formulation and packaging for a Phase
2 trial, and 3) FDA regulatory documentation and design of the Phase 2 trial required to advance to Phase 2
clinical trials in persons with MCI at risk for VCID/ADRD.
Specific Aim I: Conduct six-month chronic toxicology studies in two species to determine the toxicokinetic and
safety profiles for subcutaneously administered PNA5.
Specific Aim II. Expanded GMP manufacturing and final fill and finish of PNA5 for Phase 2 trials in VCID.
Specific Aim III: Complete regulatory assessments and documentation for submission to FDA and to
generate Phase 2 clinical trial design and plan.
Terms: <AD related dementia><ADRD><AGTR2><AGTR2 gene><AT2><Acceleration><Agonist><Alzheimer risk factor><Alzheimer's and related dementias><Alzheimer's disease and related dementia><Alzheimer's disease and related disorders><Alzheimer's disease or a related dementia><Alzheimer's disease or a related disorder><Alzheimer's disease or related dementia><Alzheimer's disease related dementia><Alzheimer's disease risk><Amendment><Amentia><Ang I (1-7)><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Arizona><Arteriosclerotic Dementia><Australia><Award><Binding><Bioavailability><Biological Availability><Biological Markers><Brain><Brain Nervous System><Brain Vascular><Cerebrovascular Circulation><Cerebrum><China><Chronic><Clinical><Clinical Protocols><Clinical Research><Clinical Study><Clinical Trials Design><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Data><Degenerative Neurologic Disorders><Dementia><Development><Diagnosis><Disease><Disorder><Disturbance in cognition><Documentation><Dose><Drug Industry><Drug Kinetics><Drugs><Encephalon><Europe><Exhibits><Formulation><G-Proteins><GTP-Binding Proteins><GTP-Regulatory Proteins><Glycopeptides><Goals><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Human><Impaired cognition><Individual><Inflammation><Inflammatory><Japan><Kilogram><Legal patent><Licensing><Link><Mainland China><Medical><Medication><Medicine><Metabolic Glycosylation><Modeling><Modern Man><Molecular Interaction><NIH RFA><Nature><Nerve Degeneration><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neuron Degeneration><O element><O2 element><Oral><Oxygen><Patents><Patients><Penetration><Peptides><Persons><Pharmaceutic Industry><Pharmaceutical Industry><Pharmaceutical Preparations><Pharmacokinetics><Phase><Phase 2 Clinical Trials><Phase II Clinical Trials><Physiologic Availability><Pre IND FDA meeting><Pre-IND mtg><Production><Protocol><Protocols documentation><Publishing><Receptor Activation><Receptor Protein><Reporting><Request for Applications><Risk><Safety><Schedule><Sight><Solubility><Specialist><Structure><Therapeutic><Time><Toxic effect><Toxicities><Toxicokinetics><Toxicology><Treatment Protocols><Treatment Regimen><Treatment Schedule><Universities><Vascular Dementia><Vascular Diseases><Vascular Disorder><Vision><Work><alzheimer risk><angiotensin I (1-7)><angiotensin-(1-7)><aqueous><bio-markers><biologic marker><biomarker><blood flow in brain><blood vessel disorder><brain blood circulation><brain blood flow><cardiac disease induced cognitive impairment><cardiovascular risk><cardiovascular risk factor><cartilage link protein><cerebral><cerebral blood flow><cerebral circulation><cerebral vascular><cerebro-vascular><cerebrocirculation><cerebrovascular><cerebrovascular blood flow><cognitive dysfunction><cognitive function><cognitive loss><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><drug/agent><experience><first in man><first-in-human><glycosylation><improved><link protein><manufacturability><manufacture><neural degeneration><neurodegeneration><neurodegenerative><neurodegenerative illness><neurological degeneration><neuronal degeneration><neuroprotection><neuroprotective><new approaches><novel><novel approaches><novel strategies><novel strategy><phase 2 designs><phase 2 trial><phase II designs><phase II protocol><phase II trial><pre-IND consultation><pre-IND discussion><pre-IND meeting><pre-Investigational New Drug meeting><pre-clinical><pre-clinical efficacy><preclinical><preclinical efficacy><prevent><preventing><programs><receptor><safety study><small molecule><subcutaneous><subdermal><trial planning><vascular cognitive impairment and dementia><vascular contributions to cognition/dementia><vascular contributions to cognitive impairment and dementia><vascular contributions to dementia><vascular dysfunction><vasculopathy><visual function>